Goserelin for Breast Cancer: Ovarian Suppression in Premenopausal Women

The clinical scenario

Many breast cancers are hormone-receptor-positive, meaning estrogen fuels their growth. In postmenopausal women, ovaries have largely stopped making estrogen, so anti-estrogen strategies focus elsewhere. But in premenopausal women, the ovaries are the dominant source of estrogen — and that changes the treatment. Goserelin (Zoladex) is used to switch the ovaries off. This use case explains the logic; treatment is always individualized with an oncologist.

Why the mechanism fits

Goserelin is a GnRH agonist. Given continuously as a depot implant, it first briefly stimulates and then suppresses the pituitary's release of LH and FSH — the hormones that tell the ovaries to make estrogen. With that signal switched off, ovarian estrogen falls to postmenopausal levels. This is called ovarian function suppression (OFS), and it starves an estrogen-driven tumor of its fuel. (For why the initial "flare" happens, see GnRH agonists vs antagonists.)

How it is used

• Combined with endocrine therapy. Ovarian suppression is usually paired with either tamoxifen or an aromatase inhibitor to block estrogen more completely. This combination is a standard approach for higher-risk premenopausal hormone-receptor-positive disease.
• A reversible alternative to surgery. Suppressing the ovaries with goserelin achieves what surgically removing them (oophorectomy) does — but reversibly, which matters for younger women who may want to preserve future fertility options.
• The depot implant. A single small implant placed under the skin of the abdomen releases drug over a month (a 3-month form also exists), so a brief clinic visit provides continuous suppression.

Protecting fertility during chemotherapy

Separately from its anti-cancer role, goserelin given during chemotherapy may reduce the risk of chemotherapy-induced ovarian failure and help preserve fertility in some premenopausal women, by putting the ovaries into a quiescent state. This is decided with an oncologist and fertility specialist.

Practical considerations

Because it creates a low-estrogen state, expected effects include hot flashes, reduced libido, and — with prolonged use — bone density loss, which is monitored. The suppression generally reverses after treatment stops. Goserelin is one component of a comprehensive plan that may include surgery, radiation, chemotherapy, and other targeted therapies.

This use case is educational and not medical advice. Breast cancer treatment decisions are made with an oncology team.